Our winner has done a stellar job at capital allocation, identifying major industry trends, investing billions in capital ahead of the shifts, and then executing brilliantly on deals.
Year-to-date fund flows highlight investors' impatience with active equity underperformance, as well as a willingness to designate new capital for taxable bond funds.
This pharmaceutical firm appears dirt-cheap, but a deeper look reveals bleak prospects.
George Paz's exemplary leadership has greatly rewarded shareholders.
Sporting a narrow moat, Abbott is set for moderate growth, but the real opportunity for investors is in rising profitability.
A weak pipeline and heavy reliance on one drug support a narrow moat, in contrast to the wide moats of most Big Pharma firms.
We think the company's approach deserves deeper scrutiny by investors.
An operational turnaround is unlikely; selective asset divestitures or the sale of the whole company appear to be the most likely courses of action.
Inflows into intermediate-term bond funds continue to dominate taxable fixed-income flows.
The market may be ignoring the boost in profitability that could occur with a bountiful 2013 crop.
Even so, threats from search newcomer Qihoo are overblown.
The company is more than a play on traditional steel markets, but higher returns may be difficult to sustain.
We see near-term visibility and long-term market share gains.
Market appreciation and flows into other stock offerings have left equities holding on to the largest chunk of invested funds.
We think the dividend is economically sustainable.
Investors craving growth should indulge in Mondelez; income seekers should favor domestic grocery unit Kraft Foods.
Morningstar recently delved into the differences between companies' competitive advantages and found that the source of a firm's moat had an impact on performance.
We've enhanced our methodology, which could result in modest fair value changes.
Our new rating system gets right to the heart of the matter: evaluating whether management teams are good stewards of shareholder capital.
After a tumultuous year, the exchange operator eyes expense savings to offset volume woes and a technology push to target sticky revenue.
Significant upside is evident as this truly global bank continues to implement its winning 'Five Filters' strategy.
Why we aren't applying for this IPO.
In his annual letter to shareholders, the Berkshire chairman and CEO offers more detail on succession planning, subsidiary performance amid the recovery, housing market predictions, and a warning for bond investors.
Their purchases hold the key to understanding demand and pricing.
The market has yet to reward this firm for its decade of diligent work.
ESPN still wears the crown in this company's kingdom despite the increasing costs of sports programming.
A record of fostering employee loyalty and driving operational excellence made 2011's winner an easy choice.
Potential investors in the newly public social game maker should consider four critical challenges before playing with the stock.
Global scale and record of innovation fall short in providing this auto parts supplier with an economic moat.
The country has to boost household consumption to maintain heady GDP growth.
Barring significant innovation, we expect Groupon's lack of a durable competitive advantage to become more obvious over the next two years.
Despite recent price falls, most European banks are not bargains.
A look at four companies presenting at the 2011 Management Behind the Moat Conference.
The stock may be a good fit for those willing to wait for higher interest rates.
StockInvestor Editor Paul Larson shares some of his views about the future.
MLPs had a great run this year but may still be attractive to income investors.
We're adding financial companies to our credit rating universe.
A new measure to help investors assess the credit risk of companies.
We think this battered drug stock is a compelling bargain.